Table 3.

Base-case results

End point	Adalimumab + standard care	Standard care alone	Incremental value
QALY	15.204	15.064	0.140
Total direct costs - public payer perspectivea	€20,598	€9950	€10,647
Adalimumab costsb	€10,550	€0	€10,550
Standard care costs	€5328	€5247	€82
Monitoring costs	€3196	€3149	€47
Colectomy costs	€1523	€1555	€-32
Total indirect costs	€73,168	€73,820	€-652
Total direct and indirect costs - social perspectivec	€93,765	€83,770	€9995
ICUR - public payer perspective	76,120 €/QALYG
ICUR - social perspective	71,457 €/QALYG

€1 = 4.2 PLN, based on the average exchange course from the year 2015

€ euro

^aTotal direct costs include: pharmacotherapy costs (biological treatment), standard care costs, monitoring costs, adalimumab administration costs, colectomy and complications after surgery costs

^bDrug and administration costs

^cTotal indirect costs included absenteeism, presenteeism, cost of early leaving the labor market